Market Resilience: Amicus Therapeutics Inc (FOLD) Finishes Strong/Weak at 10.121, Up 0.90

Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Amicus Therapeutics Inc (NASDAQ: FOLD) closed the day trading at $10.12 up 0.90% from the previous closing price of $10.03. In other words, the price has increased by $0.90 from its previous closing price. On the day, 1.98 million shares were traded. FOLD stock price reached its highest trading level at $10.3269 during the session, while it also had its lowest trading level at $9.92.

Ratios:

For a better understanding of FOLD, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.61 and its Current Ratio is at 3.03. In the meantime, Its Debt-to-Equity ratio is 3.40 whereas as Long-Term Debt/Eq ratio is at 3.34.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on May 30, 2024, initiated with a Overweight rating and assigned the stock a target price of $18.

On May 14, 2024, Guggenheim Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $13.

Morgan Stanley Upgraded its Equal-Weight to Overweight on December 19, 2023, whereas the target price for the stock was revised from $15 to $20.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 01 ’24 when Campbell Bradley L sold 7,500 shares for $10.07 per share. The transaction valued at 75,524 led to the insider holds 886,654 shares of the business.

Campbell Bradley L sold 7,500 shares of FOLD for $87,496 on Apr 01 ’24. The President and CEO now owns 886,654 shares after completing the transaction at $11.67 per share. On Mar 05 ’24, another insider, MCGLYNN MARGARET G, who serves as the Director of the company, sold 7,500 shares for $13.40 each. As a result, the insider received 100,500 and left with 59,289 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FOLD now has a Market Capitalization of 2997533952 and an Enterprise Value of 3202422528. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.08 while its Price-to-Book (P/B) ratio in mrq is 22.93. Its current Enterprise Value per Revenue stands at 7.562 whereas that against EBITDA is -65.336.

Stock Price History:

Over the past 52 weeks, FOLD has reached a high of $14.57, while it has fallen to a 52-week low of $9.02. The 50-Day Moving Average of the stock is -3.24%, while the 200-Day Moving Average is calculated to be -14.00%.

Shares Statistics:

Over the past 3-months, FOLD traded about 2.84M shares per day on average, while over the past 10 days, FOLD traded about 2347610 shares per day. A total of 293.59M shares are outstanding, with a floating share count of 287.99M. Insiders hold about 2.77% of the company’s shares, while institutions hold 106.71% stake in the company. Shares short for FOLD as of 1715731200 were 28907764 with a Short Ratio of 10.18, compared to 1713139200 on 31317181. Therefore, it implies a Short% of Shares Outstanding of 28907764 and a Short% of Float of 9.819999.

Earnings Estimates

Amicus Therapeutics Inc (FOLD) is presently subject to a detailed evaluation by 11.0 analysts, each offering their unique perspectives on its market standing.On average, analysts expect EPS of -$0.05 for the current quarter, with a high estimate of $0.02 and a low estimate of -$0.1, while EPS last year was -$0.15. The consensus estimate for the next quarter is -$0.02, with high estimates of $0.05 and low estimates of -$0.06.

Analysts are recommending an EPS of between $0.01 and -$0.35 for the fiscal current year, implying an average EPS of -$0.21. EPS for the following year is $0.23, with 10.0 analysts recommending between $0.53 and $0.11.

Revenue Estimates

11 analysts predict $121.43M in revenue for the current quarter. It ranges from a high estimate of $124.1M to a low estimate of $119.4M. As of the current estimate, Amicus Therapeutics Inc’s year-ago sales were $94.5MFor the next quarter, 11 analysts are estimating revenue of $133.32M. There is a high estimate of $135M for the next quarter, whereas the lowest estimate is $132.14M.

A total of 12 analysts have provided revenue estimates for FOLD’s current fiscal year. The highest revenue estimate was $513.6M, while the lowest revenue estimate was $507.4M, resulting in an average revenue estimate of $510.39M. In the same quarter a year ago, actual revenue was $399.36MBased on 12 analysts’ estimates, the company’s revenue will be $641.96M in the next fiscal year. The high estimate is $689.27M and the low estimate is $601.11M.

Most Popular